Global Liver Institute is proud to support H.R. 2544, the Securing the U.S. Organ Procurement and Transplantation Network Act. This bipartisan legislation responds to the urgent need for reforming the Organ Procurement Transplantation Network (OTPN), breaking up the national monopoly contract so that the Health Resources Services Administration (HRSA) can run an open, competitive process and choose from the best of the best in each field (e.g., health policy, IT, logistics, patient safety) to save more lives.
Global Liver Institute
GLOBAL LIVER INSTITUTE
Global Liver Institute Frustrated by FDA GIDAC Committee Failure to Recognize Serious, Unmet Need of Liver Patients in Rejection of Obeticholic Acid for Pre-Cirrhotic Fibrosis Due to NASH
Despite acknowledging OCA met the endpoint established by the FDA of reducing fibrosis by at least one stage, GIDAC voted against approval for treatment for NASH.
GLI Calls for Passage of the Organ Procurement and Transplantation Act
Global Liver Institute is proud to support H.R. 2544, the Securing the U.S. Organ Procurement and Transplantation Network Act. This bipartisan legislation responds to the urgent need for reforming the Organ Procurement Transplantation Network (OTPN), breaking up the national monopoly contract so that the Health Resources Services Administration (HRSA) can run an open, competitive process and choose from the best of the best in each field (e.g., health policy, IT, logistics, patient safety) to save more lives.
Global Liver Institute Applauds Dr. Monica Bertagnolli’s Nomination as Director of the National Institutes of Health
Global Liver Institute proudly supports President Biden’s nomination of Monica Bertagnolli, MD, to be the Director of the National Institutes of Health (NIH).
GLI Provides Comments on the NIDDK Advisory Council’s Report of the Health Disparities and Health Equity Working Group
Global Liver Institute provided comment on the Report of the Health Disparities and Health Equity Working Group of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Advisory Council supporting NIDDK’s recommendations.
Notable ACA Preventive Services Impacted by U.S. District Court Ruling in Texas
On March 30, 2023, a judge in the U.S. District Court in the Northern District of Texas issued a final judgment in a court case challenging the Affordable Care Act’s (ACA) requirement that private health insurance plans cover preventive services without cost-sharing for their enrollees.
Crucial Preventive Liver Screenings Imperiled by Court Ruling
On March 30, 2023, a judge in the U.S. District Court in the Northern District of Texas issued a final judgment in a court case challenging the Affordable Care Act’s (ACA) requirement that private health insurance plans cover preventive services without cost-sharing for their enrollees.
10 Things Advocates Should Know about Insurance
Value-based healthcare is a payment model for delivering healthcare in which providers (including clinics, hospitals, and more) are paid based upon conditions, episodes, outcomes, and overall health...
Spring Cleaning the U.S. Organ Transplant System
Organ transplants are gaining more and more attention in the news, and there is little wonder why.
Public Witness Testimony, Donna Cryer
GLI CEO Donna R. Cryer addresses the concerns of the liver disease community about the senseless rising incidence of liver disease and liver cancers when measures to prevent, diagnose, and treat liver disease and liver cancer are available.
Global Liver Institute Announces New Leadership of the Liver Action Network
In 2021, Global Liver Institute (GLI) launched the Liver Action Network (LAN) to better synchronize engagement across the liver advocacy community and to meet the needs of a rapidly growing cadre of liver health advocates. The LAN operates as a first-of-its-kind network that provides community member organizations a central structure for the formulation of collective health policy and programmatic solutions.
January Liver Health Policy Update
Rapid advancements to policy and committees welcomed in the new year. One of the most highlighted actions was the advancement of the nomination of Dr. Robert Califf as the incoming commissioner of the FDA to the full U.S. Senate. GLI and the patient advocacy…